DONISLECEL (LANTIDRA) FOR BRITTLE TYPE 1 DIABETES MELLITUS - A NARRATIVE REVIEW

Dr. Somi Ahmed*, Dr. Atul Maharjan, Dr. Bishal Maharjan, Dr. Tauqeer Alam Ansari and Dr. Aditya Yadav

Donislecel (Lantidra) is an excellent stem cell therapy currently in use for the management of brittle type 1 diabetes mellitus. We explored the evolving landscape of Type 1 Diabetes treatment, focusing on Donislecel (Lantidra), the first FDA-approved allogeneic cellular therapy. Integrating innovative therapies like Donislecel with existing treatment options can lay the foundation for enhancing the standard of life for individuals with Type 1 Diabetes. We analyzed four databases, namely Pubmed, Science Direct, Researchgate, and Google Scholar by searching the following keywords: (―Type 1 Diabetes Mellitus‖) AND (―Donislecel[Lantidra]‖) AND (―Stem cell therapies‖) OR (―auto-immune diabetes‖). All the available open articles in the English language were reviewed and outlined. It addresses the limitations of traditional management strategies and highlights the potential of Donislecel to enhance glycemic control and reduce insulin dependence. The paper emphasizes the critical need for further research to analyze the longstanding tolerability and safety of Donislecel, ensuring its effective integration into diabetes management strategies.